Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials
Back to article page
OriginalPaper|Updated:2021-08-27
|
Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials
Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials
中国结合医学杂志(英文版)2014年20卷第10期 页码:787-791
Affiliations:
Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences,Beijing,China
Author bio:
Funds:
Supported by the Health Industry Scientific Research Special Funding Subproject (No. 200902008-04)
Piao, Yl., Liang, Xc. , Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials., Chin. J. Integr. Med. 20, 787–791 (2014). https://doi.org/10.1007/s11655-014-1825-3
Yuan-lin Piao, Xiao-chun Liang. Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials[J]. Chinese Journal of Integrative Medicine, 2014,20(10):787-791.
Piao, Yl., Liang, Xc. , Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials., Chin. J. Integr. Med. 20, 787–791 (2014). https://doi.org/10.1007/s11655-014-1825-3DOI:
Yuan-lin Piao, Xiao-chun Liang. Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials[J]. Chinese Journal of Integrative Medicine, 2014,20(10):787-791. DOI: 10.1007/s11655-014-1825-3.
Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials
摘要
To assess the efficacy and safety of Astragalus membranaceus Injection combined with conventional therapy in the treatment of viral myocarditis. Randomized controlled trials (RCTs) of A. membranaceus Injection combined with conventional treatment compared with conventional treatment alone were included. Study population characteristics and outcome results were extracted independently by two assessors. Meta-analysis was performed for data available. Six RCTs
involving 639 participants
were included in this study. The methodological quality of the included trials was generally low
and there was high risk of publication bias in the included trials. The total effective rate of A. membranaceus Injection combined with conventional treatment was significantly higher than that of conventional treatment alone. Compared with conventional treatment
the cointervention treatment group showed significant recovery in myocardium enzyme levels and electrocardiography. Two RCTs reported there were no adverse effects from A. membranaceus Injection combined with conventional treatment. A. membranaceus Injection combined with conventional treatment appeared to be more efficacious compared with conventional treatment alone for treating viral myocarditis. However
this conclusion should be cautiously interpreted due to low methodological quality
small sample size
limited number of trials
and high risk of publication bias and other unidentified risks of bias. The safety of A. membranaceus Injection combined with conventional treatment remains uncertain.
Abstract
To assess the efficacy and safety of Astragalus membranaceus Injection combined with conventional therapy in the treatment of viral myocarditis. Randomized controlled trials (RCTs) of A. membranaceus Injection combined with conventional treatment compared with conventional treatment alone were included. Study population characteristics and outcome results were extracted independently by two assessors. Meta-analysis was performed for data available. Six RCTs
involving 639 participants
were included in this study. The methodological quality of the included trials was generally low
and there was high risk of publication bias in the included trials. The total effective rate of A. membranaceus Injection combined with conventional treatment was significantly higher than that of conventional treatment alone. Compared with conventional treatment
the cointervention treatment group showed significant recovery in myocardium enzyme levels and electrocardiography. Two RCTs reported there were no adverse effects from A. membranaceus Injection combined with conventional treatment. A. membranaceus Injection combined with conventional treatment appeared to be more efficacious compared with conventional treatment alone for treating viral myocarditis. However
this conclusion should be cautiously interpreted due to low methodological quality
small sample size
limited number of trials
and high risk of publication bias and other unidentified risks of bias. The safety of A. membranaceus Injection combined with conventional treatment remains uncertain.
关键词
Viral MyocarditisAstragalus membranaceus Injectionsystematic reviewrandomized controlled trialChinese Medicine
Keywords
Viral MyocarditisAstragalus membranaceus Injectionsystematic reviewrandomized controlled trialChinese Medicine
references
Sagar S, Liu PP, Cooper Jr LT. Myocarditis. Lancet 2012;379:738–747.
Cooper Jr LT. Myocarditis. N Engl J Med 2009;360:1526–1538.
Schulthz JC, Hilliard AA, Cooper Jr LT, Rihal CS. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc 2009;84:1001–1009.
Liu ZL, Liu ZJ, Liu JP, Kwong JS. Herbal medicines for viral myocarditis. Cochrane Database Syst Rev 2012;11:CD003711.
Chen XJ, Bian ZP, Lu S, Xu JD, Gu CR, Yang D, et al. Cardiac protective effect of Astragalus on viral myocarditis mice: comparison with Perindopril. Am J Chin Med 2006;34:493–502.
Guan FY, Liu Y, Li H, Yang SJ. Protective effects of Astragalus membranaceus Injection on viral myocarditis in mice. J Jilin Univ Med Edition (Chin) 2005;31:717–719.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996;17:1–12.
Zou FW. Astragalus Injection treatment on 48 patients with viral myocarditis. China Pharmaceuticals (Chin) 2001;10:38.
Guo YC. Effects of Astragalus membranaceus Injection on children’s viral myocarditis. Lishizhen Med Mater Med Res (Chin) 2003;14:408.
Zhang YF, Yang GD, Mao LX. Clinical observation on therapeutic effects of integrated traditional Chinese and Western medicine in treatment of acute viral myocarditis. Chin J Integr Tradit West Med Inten Crit Care (Chin) 2005;12:363–365.
Wu YX. Astragalus membranaceus Injection treatment on 119 children with viral myocarditis. China Pract Med (Chin) 2009;4:161.
Wang LJ. Effects of Astragalus membranaceus Injection on viral myocarditis in children. China Modern Med (Chin) 2011;18:55–56.
Wang YQ, Jiang AL. Clinical observation of Astragalus membranaceus Injection on viral myocarditis in children. Guide China Med (Chin) 2012;10:267–278.
Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: metaepidemiological study. BMJ 2013;346:f2304.
Gu YH, Du JX. Adverse drug reactions induced by Astragalus membranaceus Injection: analysis of 95 cases. China Pharm (Chin) 2012;23:334–336.
Efficacy of externally applied Chinese herbal drugs in treating psoriasis: A systematic review
Efficacy and safety of Flos Abelmoschus manihot (Malvaceae) on type 2 diabetic nephropathy: A systematic review
Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials
Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis
Toward Evidence-Based Chinese Medicine: Status Quo, Opportunities and Challenges
相关作者
暂无数据
相关机构
The First Hospital of Beijing University of Chinese Medicine
Department of Dermatology, China-Japan Friendship Hospital, Beijng
Janssen Pharmaceutical Ltd., Beijing
Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases
Division of Infectious Diseases, Chinese PLA Hospital